.png)
.png)
Abstract
Background and Aims: Numerous studies have shown the efficacy of controlling individual cardiovascular risk factors in preventing or slowing atherosclerotic cardiovascular disease in people with diabetes. Furthermore. large benefits are seen when multiple cardiovascular risk factors are addressed simultaneously. Here. we report glycated haemoglobin (HbA1c). low-density lipoprotein cholesterol (LDL-C). and systolic blood pressure (SBP) management at baseline (initiation of second-line treatment) among Turkish patients participating in the DISCOVER study together with the comparison versus the overall DISCOVER cohort.
Materials and Methods: DISCOVER is a 3-year. non-interventional. prospective study assessing treatment and clinical outcomes in patients with T2DM initiating second-line treatment across 37 countries. Consecutive patients with T2DM (aged ≥18 years) were invited to participate in the study if they were scheduled to initiate second-line glucoselowering treatment (add-on or switch) following oral monotherapy. dual therapy or triple therapy in first-line setting.
Results: Mean HbA1c. LDL-C and SBP were 8.8%. 131.4 mg/dL and 131.6 mmHg among the Turkish cohort compared to 8.4%. 108.1 mg/dL and 132.3 mmHg in the overall study population. respectively (Table 1). In total. 11.7% of patients had HbA1c <7% compared to 17.6% of the overall cohort. SBP <140 mmHg was observed in 62.5% of the patients compared to 67.7% of the study population. While 21.2% of patients had LDL-C levels <100 mg/dL in the results from Turkey. this proportion was 43.5% in the overall cohort (Figure 1).
Conclusion: Although poor glyceamic control is an expected finding in patients initiating second-line treatment. fewer subjects were observed to achieve HbA1c and LDL-C targets in Turkey. Therefore. cardiovascular risk factors should be systematically assessed regularly in all patients with diabetes. Modifiable abnormal risk factors such as hypertension and dyslipidemia should be treated as recommended by guidelines.